MAPT and Alzheimer disease: Novel developments in proteomic, metabolomic, and lipidomic profiling have revealed blood biomarkers, including tau protein, neurofilament light chain (NfL), amyloid-beta peptides, and inflammatory markers, that may be linked to AD pathogenesis.